Pricing Committee

Before a company’s shares trade publicly, the lead underwriters work with company management and the board to establish the final offer price and decide how many shares to allocate to each institutional investor. This coordination happens in the pricing committee, a semi-formal group whose decisions fix the price at which the public will first buy the stock. The committee’s work unfolds over hours, not days—the IPO market moves fast.

The lead underwriter’s role

The lead underwriter—typically one of the largest investment banks managing the IPO—chairs the pricing committee. The lead has already spent weeks on the roadshow, collecting non-binding indications of interest (“IOIs”) from institutional investors. These IOIs reveal demand at various price points.

The lead banker arrives at the pricing meeting with a spreadsheet: “At $15 per share, we have interest for 20 million shares. At $18, we have 15 million. At $22, we have 8 million.” This demand curve guides the discussion. The lead’s incentive is typically to price as high as possible (higher price = larger fees) while ensuring the offering sells out and trades up on the first day—a sign of success and pent-up demand.

The company’s leverage and incentives

The company wants a high price to maximize the capital raised and the founder/shareholder dilution implied by the offering. However, the company also cares about leaving room for the stock to appreciate on day one. A stock that opens at the IPO price looks flat; a stock that opens 20% above the IPO price looks hot and attracts follow-on buying.

The CFO and board members are usually first-time IPO participants. They rely on underwriter guidance, but they have veto power. If the lead suggests a price that seems too low, the company can push back. If the underwriter insists that $20 is the ceiling and the company believes $25 is justified, conflict arises—though the underwriter’s expertise usually prevails because they control the underwriting syndicate and investor relationships.

Interpreting demand signals

The IOI demand curve is not a binding order—it is an indication, revocable at the investor’s discretion. Sophisticated investors sometimes over-indicate demand at low prices (to anchor expectations) and withdraw at higher prices. The pricing committee must be skeptical.

The lead underwriter’s analysts provide comps analysis: “Peers in the sector trade at 8–12x EBITDA. This company should trade at 9–10x.” They also provide a DCF valuation: “Fair value is $22–$26 per share.” These frameworks help bound the discussion and signal to the board that the price is reasonable, not arbitrary.

The allocation strategy

Once a price is set, the committee addresses allocation. If the offering is $200 million at $20 per share, that is 10 million shares to distribute. Demand may be 2–3x oversubscribed—investors have indicated interest for 20–30 million shares. The committee must allocate the 10 million.

Allocations are almost never distributed pro-rata (to each investor proportionally to their demand). Instead, the lead underwriter exercises discretion: top-tier institutional investors (mutual funds, insurance companies, pensions) receive larger allocations; retail investors (through retail brokers in the syndicate) may receive small allocations or none; hedge funds sometimes receive nothing.

This discretion is a form of market power. Investors who expect to be favored in the IPO allocation cultivate relationships with the lead underwriter and promise to be “loyal” investors in the aftermarket—i.e., not to flip shares immediately.

Stabilization and the underwriter’s option

After pricing, the underwriter typically has a “greenshoe” or “overallotment option”—the right to sell up to 15% additional shares (the “green shoe”) beyond the original allocation. If demand is extremely strong, the greenshoe is exercised, raising extra capital. If demand is weak, the underwriter buys shares in the open market to stabilize the price and prevent a post-IPO decline.

This stabilization is disclosed in the final prospectus, but many IPO participants are unaware of it. The greenshoe is a hedge for the underwriter—it reduces the risk of the offering at the expense of (potentially) slightly higher share dilution for existing shareholders.

Quiet period and communication constraints

Once the pricing committee sets the price, the company enters a restricted “quiet period.” Under SEC rules, the company cannot make public statements about business performance, forward guidance, or the IPO itself (beyond the final prospectus). This prevents the company from hyping the stock or inadvertently misleading investors.

The pricing committee members are aware of these restrictions, so the price-setting discussion is the last chance for the company to make a case for a higher (or lower) price. After pricing, the company is silent until after the quiet period (typically 25 days post-IPO).

Dispute resolution and leverage

Occasionally, the company and lead underwriter disagree on price. If the company insists on a price that the underwriter believes is too aggressive, the underwriter can threaten to reduce the size of the offering or withdraw. Conversely, if the company wants a lower price (to ensure a “pop” on day one), the underwriter may push back.

In most cases, the underwriter prevails because it has the institutional relationships and market expertise. However, companies with strong brands (e.g., Uber, Airbnb) have more leverage to negotiate. These firms have demonstrated consumer or enterprise demand, so investors are eager; the underwriter cannot easily walk away.

Aftermarket performance and reputation

The pricing committee’s success is measured by whether the stock trades well post-IPO. A stock that closes its first day 30–50% above the IPO price is a “hot” IPO, but it signals underpricing—the company could have raised more capital. A stock that trades below the IPO price is a failure, and the underwriter’s reputation suffers (limited partners and future clients will be wary).

The sweet spot is a 15–20% first-day pop. This signals success without suggesting the offering was mispriced. It also satisfies both the company (they raised capital at a reasonable valuation) and investors (they have immediate mark-to-market gains).